Skip to main content

Advertisement

Table 5 MIC of different antibiotics after the association with compound 4 at MIC/2, MIC/4 against seven MDR bacteria strains

From: Antibacterial and antibiotic-modifying activities of fractions and compounds from Albizia adianthifolia against MDR Gram-negative enteric bacteria

Antibioticsa Bacterial strainsb, MIC (μg/mL) of antibiotics in the absence and presence of compound 4
Compounds concentration PA124 KP55 ATCC11296 EA27 ATCC13048 AG102 ATCC10536 PBSS (%)
CIP 0 2 0.5 0.5 0.5 4 2 0.125  
  CMI/2 2 (1)I 0.5(1)I 0.25(0.5)S 0.25(0.5)S 0.5(0.125)S 0.5(0.25)S 0.125(1)I (4/7) 57.14%
CMI/4 2 (1)I 0.5(1)I 0.25(0.5)S 0.25(0.5)S 0.5(0.125)S 0.5(0.25)S 0.125(1)I (4/7) 57.14%
ERY 0 > 32 4 > 32 > 32 > 32 16 16  
  CMI/2 32 (0.5)S 2(0.5)S 4(< 0.125)S 32 (0.5)S 4(< 0.125)S 4 (0.25)S 8 (0.5)S (7/7) 100%
CMI/4 32 (0.5)S 2(0.5)S 4(< 0.125)S 32 (0.5)S 8(< 0.25)S 4 (0.25)S 8 (0.5)S (7/7) 100%
GEN 0 > 4 2 > 4 4 4 > 4 4  
  CMI/2 4(0.5)S 1(0.5)S 0.0625(< 0.015)S 1 (0.25)S 2(0.5)S 4(0.5)S 0.5(0.125)S (7/7) 100%
CMI/4 4(0.5)S 2(1)I 0.0625(< 0.015)S 1 (0.25)S (0.5)S 4(0.5)S 2(0.5)S (6/7) 85.71%
KAN 0 0.5 2 4 4 16 16 4  
  CMI/2 < 0.125(0.25)S 1(0.5)S 2(0.5)S 4(1)I 16(1)I 16(1)I 4(1)I (3/7) 42.85%
CMI/4 < 0.125(0.25)S 2(1)I 2(0.5)S 4(1)I 16(1)I 16(1)I 4(1)I (2/7) 28.57%
NOR 0 > 16 16 1 16 16 2 1  
  CMI/2 8(< 0.5)S 2(0.125)S 0.5(0.5)S 4(0.25)S 8(0.5)S 2(1)I 0.5(0.5)S (6/7) 85.71%
CMI/4 8(< 0.5)S 2(0.125)S 0.5(0.5)S 8(0.5)S 8(0.5)S 2(1)I 0.5(0.5)S (6/7) 85.71%
STR 0 > 32 > 32 > 32 > 32 > 32 > 32 > 32  
  CMI/2 32(0.5)S 32(0.5)S 32(0.5)S 16(< 0.5)S 32(0.5)S 16(< 0.5)S 2(< 0.062)S (7/7) 100%
CMI/4 32(0.5)S 32(0.5)S 32(0.5)S 16(< 0.5)S 32(0.5)S 16(< 0.5)S 2(< 0.062)S (7/7) 100%
TET 0 8 0.125 > 16 > 16 > 16 > 16 16  
  CMI/2 4(0.5)S 0.0625(0.5)S 0.5(< 0.031)S 4(< 0.25)S 0.5(< 0.031)S 2(< 0.125)S 0.125(0.007)S (7/7) 100%
CMI/4 4(0.5)S 0.0625(0.5)S 0.5(< 0.031)S 8(< 0.5)S 0.5(< 0.031)S 2(< 0.125)S 0.125(0.007)S (7/7) 100%
  1. aAntibiotics [CIP Ciprofloxacin, ERY Erythromycin, GEN Gentamycin, KAN Kanamycin, NOR Norfloxacin, STR Streptomycin, TET Tetracyclin]. bBacteria: Escherichia coli [ATCC10536, AG102], Pseudomonas aeruginosa [PA124], Enterobacter aerogenes [ATCC13048, EA27], Klebsiella pneumoniae [ATCC11296, KP55]. PBSS: Percentage of bacteria strain on which synergism has been observed; S: Synergy; I: Indifference; (): FIC (Fractional Inhibitory Concentration) of the antibiotics after association with compounds, 0: MIC of the antibiotic alone